Molecular Genetics of Hereditary Ovarian Cancer

ONCOLOGY

Volumn 12, Issue 3, 1998, Pages 399-406

  Boyd, Jeff ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARRIER PROTEIN; DNA BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MSH2; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

DNA REPAIR; FEMALE; FORECASTING; GENETIC DISORDER; GENETICS; HUMAN; OVARY TUMOR; RESEARCH; REVIEW; RISK ASSESSMENT;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARRIER PROTEINS; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FORECASTING; GENETIC DISEASES, INBORN; HUMANS; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RESEARCH; RISK ASSESSMENT; TRANSCRIPTION FACTORS;

EID: 0032013802     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Parazzini F, Franceschi S, La Veechia C, et al. The epidemiology of ovarian cancer. Gynecol Oncol 43:9-23, 1991.
2. Bishop JM: Cancer: The rise of the genetic paradigm. Genes Dev 9:1309-1315, 1995.
3. Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139-146, 1993
4. Cavenee WK, Dryja TP, Phillips RA, et al.: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983.
5. Claus EB, Schildkraut JM, Thompson WD, et al.: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996.
6. Narod SA, Ford D, Devilee P, et al.: An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56:254-264, 1995.
7. Narod S, Ford D, Devilee P, et al.: Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 57:957-958, 1995.
8. Lynch HT, Smyrk TC, Watson P, et al.: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer. Gastroenterology 104:1535-1549, 1993.
9. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-85, 1993.
10. Bewtra C, Watson P, Conway T, et al.: Hereditary ovarian cancer. A chincopathological study. Int J Gynecol Pathol 11:180-187, 1992.
11. Nystrom-Lahti M, Parsons R, Sistonen P, et al. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 55:659-665, 1994.
12. Nicolaides NC, Papadopoulos N, Liu B, et al.: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75-80, 1994.
13. Easton DF., Bishop DT, Ford D, et al.: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families: The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678-701, 1993.
14. Miki Y, Swensen J, Shattuck-Edens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994.
15. Chen Y, Farmer AA, Chen C-F, et al.: BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56:3168-3172, 1996
16. Koonin EV, Altschul S, Bork P: BRCA1 protein products: Functional motifs. Nature Genet 13-266-268, 1996.
17. Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature 382:678-679, 1996.
18. Monteiro ANA, August A, Hanafusa H: Evidence for a transcnptional activation function for BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:13595-13599, 1996.
19. Scully R, Anderson SF, Chao DM. et al: BRCA1 is a component of the UNA polymerase II holoenzyme. Proc Natl Acad Sci USA 94:5605-5610, 1997.
20. Marquis ST, Rajan JV, Wynshaw-Boris A, et al.: The developmental pattern of BRCA1 expression implies a role in differentiation of breast and other tissues. Nature Genet 11:17-26, 1995.
21. Scully R, Chen J, Plug A, et al.: Association of BRCA1 with Rad51 in mitotic and metotic cells. Cell 88:265-275, 1997
22. Breast Cancer information Core. NHGRI Web Site (http://wwvv.nhgri.nih.gov/ Intramural_research/Lab_transfer/Bic), 1997.
23. Roa BB, Boyd AA, Volcik K. et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 14:185-187, 1996.
24. Struewing JP, Abeliovich D, Peretz T, et al.: The carrier frequency of the BRCA1 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nature Genet 11:198-200, 1995
25. Takahashi H, Behbakht K, McGovern PE, et al.: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998-3002, 1995.
26. Matsushima M. Kobayashi K. Emi M. et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: Four germ-line mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-1956, 1995.
27. Stratton JF, Gayther SA, Russell P, et al.: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125-1130, 1997.
28. Wooster R, Bignell G, Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995.
29. Tavtigian SV, Simard J, Rommens J, et al.: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 12:333-337, 1996.
30. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al.: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet 13:117-119, 1996.
31. Takahashi H, Chiu H-C, Bandera CA, et al.: Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56:2738-2741, 1996.
32. Foster KA, Harrington P. Kerr J, et al.: Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56:3622-3625, 1996.
33. Wang SC, Lin SH, Su LK. et al: Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Comm 234:247-251, 1997.
34. Spillman MA, Bowcock AM: BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 13:1639-1645, 1996.
35. Conner F, Smith A, Wooster R, et al.: Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. Hum Mol Genet 6:291-300, 1997.
36. Rajan JV, Marquis ST, Gardner HP, et al.: Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 184:385-401, 1997.
37. Sharan SK, Morimatsu M, Albrecht U, et al.: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810, 1997.
38. Milner J, Ponder B, Hughes-Davies L, et ah Transcnptional activation functions in BRCA2. Nature 386:772-773, 1997.
39. Oddoux C, Struewing JP, Clayton CM, et al.: The carrier frequency of the BRCA2 6174delT mutation among Askenazi Jewish individuals is approximately 1%. Nature Genet 14:188-190, 1996.
40. Abeliovich D, Kaduri L, Lerer L et al: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Askenazi women. Am J Hum Genet 60:505-514, 1997.
41. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives J Natl Cancer Inst 87:1114-1125, 1995.
42. Fishel R, Kolodner R. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5:382-395, 1995.
43. Liu B, Parsons R, Papadopoulos N, et al.: Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nature Med 2:169-174, 1996.
44. Kolodner RD: Mismatch repair: Mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 20:397-401, 1995.
45. Kane MF, Loda M, Gaida GM, et al.: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808-811, 1997.
46. de Wind N, Dekker M, Berns A, et al.: Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82:321-330, 1995.
47. Baker SM, Bronner CE, Zhang L, et al.: Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 82:309-320, 1995.
48. Baker SM, Plug AW, Prolla TA, et al.: Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nature Genet 13:336-342, 1996.
49. Parsons R, Myeroff L, Liu B, et al.: Micro-satellite instability and mutations of the transforming growth factor b type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550, 1995.
50. Rampino N, Yamamoto H, Ionov Y, et al.: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997.
51. Malkhosyan S, Rampino N, Yamamoto H, et al: Frameshift mutator mutations. Nature 382:499-500, 1996.
52. Gayther SA, Warren W, Mazoyer S, et al.: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet 11:428-433, 1995.
53. Gayther SA, Mangion J, Russell P, et al.: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene Nature Genet 15:103-105, 1997.
54. Phelan CM, Rebbeck TR, Weber BL, et al.: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 12:309-311, 1996.
55. Easton DF, Ford D, Bishop DT, et al.: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265-271, 1995.
56. Wooster R, Neuhausen SL, Mangion J, et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, Science 265:2088-2090, 1994.
57. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997.
58. Levy-Lahad E, Catane R, Eisenberg S, et al.: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breastovarian cancer families. Am J Hum Genet 60:1059-1067, 1997.
59. Rubin SC, Benjamin I, Behbakht K, et al.: Clinical and pathologic features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413-1416, 1996.
60. Marcus JN, Watson P, Page DL, et al.: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996.
61. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510, 1997.
62. Tirkkonen M, Johannsson O, Agnarsson BA, et al.: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227, 1997.
63. Boyd J, Rubin SC: Hereditary ovarian cancer: Molecular genetics and clinical implications Gynecol Oncol 64:196-206, 1997.
64. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996.
65. Burke W, Petersen G, Lynch P, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: 1. Hereditary nonpolyposis colon cancer: Cancer Genetics Studies Consortium. JAMA 277:915-919, 1997.
66. Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2: Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997.
67. Lynch HT, Lemon SJ, Durham C, et al.: A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79:2219-2228, 1997.
68. Botkin JR, Croyle RT, Smith KR, et al.: A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J Natl Cancer Inst 88:872-882, 1996.